Table 1

Baseline patient characteristics by MBDA category

MBDA score and category
N (patients)
n=17 433
<30 (low)
30–44 (moderate)
>44 (high)
Age in years, mean (SD)68.9 (10.7)66.3 (11.4)69.2 (10.3)69.5 (10.6)
MBDA score*, mean (SD)44.1 (14.0)21.9 (5.3)37.9 (4.1)55.8 (9.2)
Female, %
Race, %
Comorbidities, %
 Acute myocardial infarction†
 Coronary heart disease20.316.119.622.0
 Heart failure7.
 Abdominal aortic aneurysm1.
 Peripheral arterial disease3.
 Atrial fibrillation7.
 Chronic kidney disease11.66.19.714.8
 Chronic obstructive pulmonary disease25.419.323.029.2
Medication use, %
 Biologic DMARDs37.040.838.035.0
 HCQ, LEF or SSZ40.238.939.241.4
Methotrexate, mg/week
 No use45.749.445.944.5
 >10 to ≤
 >15 to ≤
 Not use biologic or non-biologic DMARDs13.916.714.512.7
Prednisone-equivalent steroid dose, mg/day
 No use46.757.551.239.7
 0 to ≤7.533.230.133.733.7
Health behaviour, %
  Prostate-specific antigen‡48.253.750.344.2
 Papanicolaou smear§12.317.213.110.4
 Qualified for Medicare for reason other than age
(eg, disability)
  • Note: Population shown was included for the SIE analysis. After exclusion for prevalent CHD, a subgroup of 16 796 patients was included in the MI/CHD analysis. Proportions may not sum exactly to 100% due to rounding.

  • *Measured at the time of the first MBDA test, using data from the preceding 12 months.

  • †These patients were included in infection analysis but excluded from MI and CHD analyses.

  • ‡Men only.

  • §Women only.

  • CHD, coronary heart disease; DMARD, disease-modifying antirheumatic drugs; HCQ, hydroxychloroquine; LEF, leflunomide; MBDA, multibiomarker disease activity; MI, myocardial infarction; SIE, serious infection event; SSZ, sulfasalazine.